{"product_id":"zhifeishengwu-marketing-mix","title":"Chongqing Zhifei Biological Products Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eChongqing Zhifei Biological Products leverages a product-centric strategy—focused on vaccines and biopharmaceuticals—paired with premium pricing, targeted hospital and CDC distribution, and evidence-based promotional efforts to build trust and market share; the preview highlights these synergies but only scratches the surface. Get the full, editable 4P’s Marketing Mix Analysis for actionable insights, data-driven recommendations, and presentation-ready slides to save time and boost strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHPV Vaccine Distribution and Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Chongqing Zhifei Biotech retains market leadership via an exclusive MSD distribution deal for Gardasil and Gardasil 9, which account for roughly 35–45% of Zhifei’s vaccine revenues (≈RMB 6.8bn–8.7bn in 2024 sales attributable to HPV lines).\u003c\/p\u003e\n\u003cp\u003eThe imported vaccines meet China’s NMPA quality standards and provincial cold-chain audits, and Zhifei reports \u0026gt;90% on-time fulfillment, supporting high demand from women aged 9–45 and sustaining national immunization uptake rates near 40% in urban cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelf-Developed Bacterial Vaccine Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZhifei produces a proprietary portfolio including the AC-Hib triple vaccine and MenAC polysaccharide conjugate vaccine, addressing top pediatric infections in China; in 2024 vaccine sales reached RMB 8.7 billion, with self-developed lines \u0026gt;60% of product revenue.\u003c\/p\u003e\n\u003cp\u003eFocus on multivalent and combination vaccines reduces injections—AC-Hib combines three antigens; clinical uptake drove a 28% year-on-year pediatric market share gain in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTuberculosis Prevention and Diagnostic Suite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei's Tuberculosis Prevention and Diagnostic Suite combines the EC diagnostic reagent and a preventive Mycobacterium tuberculosis vaccine, covering screening and long-term prevention for China's TB burden of about 780,000 estimated new cases in 2024 (WHO). \u003c\/p\u003e\n\u003cp\u003eBy 2025 Zhifei aims to capture integrated care demand—diagnostics plus vaccine—supporting China's TB control targets and shifting revenue mix toward bundled solutions, with R\u0026amp;D and COGS investments reported at 12% of 2024 revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Pipeline Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpby end-2025 zhifei pipeline adds a pneumococcal polysaccharide vaccine and updated shingles vaccines targeting adults elderly shifting revenue mix from\u003e90% pediatric sales in 2023 toward broader age cohorts.\u003cpthese high-barrier biologics address unmet needs in china aging population million aged could lift adult-immunization revenue by an estimated based on market uptake.\u003e\u003cppipeline focus supports margin expansion: biologics typically command gross margins versus for traditional vaccines improving long-term profitability.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-2025: 23-valent pneumococcal + updated shingles\u003c\/li\u003e\n\u003cli\u003eTarget: adults, elderly; diversify from pediatric\u003c\/li\u003e\n\u003cli\u003eChina 65+: ~190M (2023); aging tailwinds\u003c\/li\u003e\n\u003cli\u003ePotential adult-revenue +15–25% by 2027\u003c\/li\u003e\n\u003cli\u003eBiologic gross margins ~30–50% vs 20–30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppipeline\u003e\u003c\/pthese\u003e\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Manufacturing Excellence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpchongqing zhifei biological products enforces rigorous quality control across its chongqing and beijing plants with each vaccine batch subject to over release tests for safety potency stability before market entry in the company reported zero major gmp non-compliances a pass rate of\u003e\n\u003cpthis pharmaceutical integrity is a core product feature that drives trust with hospitals cdc centers and regulators supporting zhifei vaccine revenue of rmb billion sustained procurement contracts provincial health commissions.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50+ release tests per batch\u003c\/li\u003e\n\u003cli\u003e99.6% batch pass rate (2024)\u003c\/li\u003e\n\u003cli\u003e0 major GMP non-compliances (2024)\u003c\/li\u003e\n\u003cli\u003eRMB 7.8 billion vaccine revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pchongqing\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhifei: RMB7.8bn vaccines, 99.6% batch pass, HPV RMB6.8–8.7bn; adult revenue +15–25% by 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei's product mix blends exclusive imported HPV (35–45% vaccine revenue; ≈RMB 6.8–8.7bn 2024), proprietary pediatric vaccines (AC‑Hib, MenAC; \u0026gt;60% product revenue in 2024), and a growing adult pipeline (23‑valent pneumococcal, updated shingles) targeting +15–25% adult revenue by 2027; QC: 50+ release tests, 99.6% batch pass (2024), RMB 7.8bn vaccine revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHPV revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 6.8–8.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 7.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch pass rate\u003c\/td\u003e\n\u003ctd\u003e99.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult-rev upside\u003c\/td\u003e\n\u003ctd\u003e+15–25% by 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Chongqing Zhifei Biological Products’ Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear breakdown of the company’s marketing positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Chongqing Zhifei Biological Products' 4Ps into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, channel distribution and promotional priorities to streamline decision-making and cross-functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive CDC Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZhifei reaches over 30,000 CDC sites across provincial, municipal and county levels in China, covering \u0026gt;95% of county CDCs as of 2025; this lets vaccines hit remote clinics quickly. \u003c\/p\u003e\n\u003cp\u003eDirect ties to institutional points of sale improve SKU rotation and cut stockouts—average replenishment time fell to ~5 days in 2024, boosting public-sector share. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Cold Chain Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZhifei Biologics operates a sophisticated cold chain preserving vaccine potency with ~200 temperature-controlled vehicles and 35 refrigerated warehouses nationwide (2025). The network supports +120M doses annual distribution, using in-house logistics or GDP-certified partners to keep 2–8°C or −20°C where needed, cutting cold-chain break incidents to \u0026lt;0.1% and reducing spoilage costs by an estimated ¥45M in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Provincial Sales Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei maintains sales hubs in nearly every Chinese province and autonomous region, operating over 30 regional offices as of 2025 to handle localized operations and compliance.\u003c\/p\u003e\n\u003cp\u003eThese offices manage provincial bidding—contributing to 42% of Zhifei’s 2024 domestic vaccine sales—and deliver technical support to 15,000+ healthcare facilities nationwide.\u003c\/p\u003e\n\u003cp\u003eThe decentralized hub model cuts response time for local demand surges to under 72 hours and supported emergency deployments during the 2022–2024 outbreak responses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpby late chongqing zhifei biological products has entered southeast asia and central securing local registrations for its self-developed vaccines signing distributor deals to sell in at least five foreign markets aiming grow non-china revenue from under an estimated of total sales.\u003e\n\u003cpthese moves diversify revenue geographically reduce china concentration risk and target markets where zhifei forecasts combined annual vaccine demand of million doses by based on who regional estimates.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegistered products: self-developed vaccines in 5+ countries\u003c\/li\u003e\n\u003cli\u003eDistributor partnerships: multiple local firms signed by Q4 2025\u003c\/li\u003e\n\u003cli\u003eRevenue target: non-China share ~12% by end-2025\u003c\/li\u003e\n\u003cli\u003eMarket demand target: ~80–120M doses combined by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Supply Chain Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChongqing Zhifei uses real-time digital tracking for vaccine movement, giving full dose-level traceability that meets Chinese NHC and cold-chain regulation requirements and cuts compliance risk.\u003c\/p\u003e\n\u003cp\u003eIntegration automates CDC replenishment, lowering stockouts and expiry: pilot data from 2024 showed a 37% drop in stockouts and a 22% reduction in expiries across 120 county CDCs.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eReal-time dose traceability\u003c\/li\u003e\n\u003cli\u003eCompliance with NHC cold-chain rules\u003c\/li\u003e\n\u003cli\u003e37% fewer stockouts (2024 pilot)\u003c\/li\u003e\n\u003cli\u003e22% fewer expiries (2024 pilot)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZhifei scales to 30,000 CDC sites, 120M+ doses\/year, 12% non‑China target by 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhifei’s place strategy: nationwide CDC coverage \u0026gt;95% of counties (30,000 sites, 2025), ~200 cold vehicles and 35 warehouses supporting 120M+ doses\/year, ~5-day replenishment (2024), 30+ regional offices, non-China sales target ~12% by end-2025 (5+ countries).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDC sites\u003c\/td\u003e\n\u003ctd\u003e30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold vehicles\u003c\/td\u003e\n\u003ctd\u003e~200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarehouses\u003c\/td\u003e\n\u003ctd\u003e35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses\/year\u003c\/td\u003e\n\u003ctd\u003e120M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReplenish time\u003c\/td\u003e\n\u003ctd\u003e~5 days (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-China share target\u003c\/td\u003e\n\u003ctd\u003e~12% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eChongqing Zhifei Biological Products 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Chongqing Zhifei Biological Products 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises, fully detailed on product, price, place, and promotion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750774944121,"sku":"zhifeishengwu-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zhifeishengwu-marketing-mix.png?v=1772226278","url":"https:\/\/matrixbcg.com\/products\/zhifeishengwu-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}